Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities

Immune checkpoint inhibitors (ICIs) are newer, immunotherapy-based drugs that have been shown to improve survival in advanced non-small cell lung cancer (NSCLC). Unlike traditional chemotherapeutic agents, ICIs work by boosting the body’s natural tumor killing response. However, this unique mechanis...

Full description

Saved in:
Bibliographic Details
Published in:Chest
Main Authors: Suresh, Karthik, Naidoo, Jarushka, Lin, Cheng Ting, Danoff, Sonye
Format: Artigo
Language:Inglês
Published: American College of Chest Physicians 2018
Subjects:
Special Feature
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6335259/
https://ncbi.nlm.nih.gov/pubmed/30189190
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.chest.2018.08.1048
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items